NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
Astellas Pharma Inc
Merck Sharp & Dohme LLC
University of Chicago
Gustave Roussy, Cancer Campus, Grand Paris
Hoffmann-La Roche
M.D. Anderson Cancer Center
Eikon Therapeutics
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Centre Francois Baclesse
Sanofi